We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.01% | 75.75 | 75.94 | 75.98 | 49,389 | 11:33:04 |
From May 2021 to May 2024
By Matt Grossman
AstraZeneca PLC said Friday its Imfinzi drug shows a clinically meaningful benefit in overall survival and progression-free survival at five years for patients with unresectable stage-three non-small-cell lung cancer who hadn't progressed following concurrent chemoradiation therapy.
Results from a Phase 3 trial showed an estimated five-year overall survival rate of 42.9% for patients treated with Imfinzi, compared with those who received a placebo after chemoradiation therapy, AstraZeneca said. Median overall survival was 47.5 months for Imfinzi patients, versus 29.1 months for placebo patients.
"Historically, only 15% to 30% of these patients survived five years but these results show that with up to one year of treatment with Imfinzi, an estimated 43% of patients are still alive at five years," Dr. David Spigel, an investigator in the Phase 3 trial, said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 04, 2021 07:50 ET (11:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
